70 related articles for article (PubMed ID: 21084897)
1. Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases.
Chawla S; Zhang Y; Wang S; Chaudhary S; Chou C; O'Rourke DM; Vossough A; Melhem ER; Poptani H
J Comput Assist Tomogr; 2010; 34(6):836-41. PubMed ID: 21084897
[TBL] [Abstract][Full Text] [Related]
2. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Cianfoni A; Niku S; Imbesi SG
AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993
[TBL] [Abstract][Full Text] [Related]
3. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance spectroscopy detection of high lipid levels in intraaxial tumors without central necrosis: a characteristic of malignant lymphoma.
Yamasaki F; Takayasu T; Nosaka R; Amatya VJ; Doskaliyev A; Akiyama Y; Tominaga A; Takeshima Y; Sugiyama K; Kurisu K
J Neurosurg; 2015 Jun; 122(6):1370-9. PubMed ID: 25748300
[TBL] [Abstract][Full Text] [Related]
5. Machine learning decision tree models for multiclass classification of common malignant brain tumors using perfusion and spectroscopy MRI data.
Vallée R; Vallée JN; Guillevin C; Lallouette A; Thomas C; Rittano G; Wager M; Guillevin R; Vallée A
Front Oncol; 2023; 13():1089998. PubMed ID: 37614505
[TBL] [Abstract][Full Text] [Related]
6. Conventional and Advanced Magnetic Resonance Imaging Assessment of Non-Enhancing Peritumoral Area in Brain Tumor.
Scola E; Del Vecchio G; Busto G; Bianchi A; Desideri I; Gadda D; Mancini S; Carlesi E; Moretti M; Desideri I; Muscas G; Della Puppa A; Fainardi E
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296953
[TBL] [Abstract][Full Text] [Related]
7. Differentiating glioblastoma from primary central nervous system lymphoma of atypical manifestation using multiparametric magnetic resonance imaging: A comparative study.
Feng A; Li L; Huang T; Li S; He N; Huang L; Zeng M; Lyu J
Heliyon; 2023 Apr; 9(4):e15150. PubMed ID: 37095995
[TBL] [Abstract][Full Text] [Related]
8. Imaging of White Matter Injury Correlates with Plasma and Tissue Biomarkers in Pediatric Porcine Model of Traumatic Brain Injury.
Shin SS; Chawla S; Jang DH; Mazandi VM; Weeks MK; Kilbaugh TJ
J Neurotrauma; 2023 Jan; 40(1-2):74-85. PubMed ID: 35876453
[TBL] [Abstract][Full Text] [Related]
9. Emerging MR Imaging and Spectroscopic Methods to Study Brain Tumor Metabolism.
Kumar M; Nanga RPR; Verma G; Wilson N; Brisset JC; Nath K; Chawla S
Front Neurol; 2022; 13():789355. PubMed ID: 35370872
[TBL] [Abstract][Full Text] [Related]
10. Preoperative blood testing for glioblastoma, brain metastases, and primary central nervous system lymphoma differentiation.
Wang SQ; Yuan Q; Zhang GT; Qian HP; Liu ZD; Wang JW; Cai HQ; Wan JH
Transl Cancer Res; 2022 Jan; 11(1):63-71. PubMed ID: 35261885
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.
Krebs S; Barasch JG; Young RJ; Grommes C; Schöder H
Ann Lymphoma; 2021 Jun; 5():. PubMed ID: 34223561
[TBL] [Abstract][Full Text] [Related]
13. Radiomic Based Machine Learning Performance for a Three Class Problem in Neuro-Oncology: Time to Test the Waters?
Priya S; Liu Y; Ward C; Le NH; Soni N; Pillenahalli Maheshwarappa R; Monga V; Zhang H; Sonka M; Bathla G
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073840
[TBL] [Abstract][Full Text] [Related]
14. Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.
Chawla S; Shehu V; Gupta PK; Nath K; Poptani H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918043
[TBL] [Abstract][Full Text] [Related]
15. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.
Overcast WB; Davis KM; Ho CY; Hutchins GD; Green MA; Graner BD; Veronesi MC
Curr Oncol Rep; 2021 Feb; 23(3):34. PubMed ID: 33599882
[TBL] [Abstract][Full Text] [Related]
16. Differential imaging of atypical demyelinating lesions of the central nervous system.
Paoletti M; Muzic SI; Marchetti F; Farina LM; Bastianello S; Pichiecchio A
Radiol Med; 2021 Jun; 126(6):827-842. PubMed ID: 33486703
[TBL] [Abstract][Full Text] [Related]
17.
Johnson DR; Fogh SE; Giannini C; Kaufmann TJ; Raghunathan A; Theodosopoulos PV; Clarke JL
Neurooncol Pract; 2015 Sep; 2(3):106-121. PubMed ID: 31386093
[TBL] [Abstract][Full Text] [Related]
18. Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.
Chawla S; Lee SC; Mohan S; Wang S; Nasrallah M; Vossough A; Krejza J; Melhem ER; Nabavizadeh SA
Neuroradiol J; 2019 Aug; 32(4):250-258. PubMed ID: 31050313
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis.
Lu X; Xu W; Wei Y; Li T; Gao L; Fu X; Yao Y; Wang L
Neurol Sci; 2019 May; 40(5):947-956. PubMed ID: 30706241
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
